Drug intelligence / Profile preview

V540A

Development stage: Phase 2
Lead developer: Merck
Modality: Vaccines & Immunotherapeutics
Administration: Intramuscular

Overview

**V540A** is an investigational multivalent human papillomavirus (HPV) vaccine developed by Merck Sharp & Dohme LLC. It is designed to elicit immune responses against the 9 HPV types covered by the approved GARDASIL®9 vaccine (HPV 6, 11, 16, 18, 31, 33, 45, 52, 58) plus additional unique HPV types not covered by GARDASIL®9, with the goal of providing broader protection against HPV-related cancers and precancerous lesions. The vaccine is administered intramuscularly in multiple doses and is being evaluated for safety, tolerability, and immunogenicity compared to GARDASIL®9 in early-phase clinical trials.[3][5]

Beyond the preview

Go deeper on V540A.

Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.

Clinical trials

Follow clinical development from study design and recruitment through results.

Trial phase
Status
Readouts

Indications & development

Explore development by indication, patient population, and geography.

Indications
Development status
Countries

Licensing & deals

Trace asset ownership, licensing agreements, and commercial partnerships.

Partners
Deal terms
Milestones

Patents & exclusivity

Explore the patent landscape and regulatory exclusivity around an asset.

Patents
Expiration dates
Exclusivity

Competitive landscape

Compare development programs by target, modality, and indication.

Competing assets
Targets
Development stage

Research & analysis

Connect source evidence and development news to your research questions.

Publications
News
Analysis

Bring the full picture into focus.

See how Gosset can support your research on V540A.

Explore the full profile